Background/Aims: Programmed death ligand1(PD-L1) plays a role in the development and progression of non-small cell lung cancer (NSCLC). This study aimed to identify miRNA(s) that are responsible for regulation of expression of PD-L1 in NSCLC, and to investigate the role of PD-L1 in regulation of the cell cycle in NSCLC. Methods: We predicted the target miRNA of PD-L1, which was miR-140, using the online tools TargetScan and miBase. In NSCLC cells obtained from clinical specimens, in addition to A549 and NCI-H1650 cell cultures, western blots were used to detect the level of expression of proteins, while real-time PCR was used to determine the level of expression of PD-L1, miR-140, cyclin E, and β-actin. Transfection with miR-140 mimics, miR-140 inhibitors, and PD-L1 siRNA were conducted using commercial kits. To determine whether miR-140 directly binds PD-L1, a luciferase reporter gene with wild type or mutated PD-L1 was used. Cell viability was measured with the MTT assay, and PI staining was used for cell cycle analysis. Results: We found low expression of miR-140 and high expression of PD-L1 and cyclin E in NSCLC cells. Over-expression of miR-140 suppressed the expression of PD-L1 by directly binding its 3' UTR, and was also associated with decreased expression of cyclin E and inhibition of cellular proliferation in A549 and NCI-H1650 cells. Inhibition of PD-L1, in the absence of manipulations to miR-140, also decreased the expression of cyclin E. Conclusion: We conclude that miR-140 directly suppresses PD-L1 and inhibits the miR-140/ PD-L1/cyclin E pathway in NSCLC.
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Introduction
Lung cancer is the leading cause of cancer death worldwide, especially in China [1, 2] . Though multimodal therapies are often used in patients with non-small cell lung cancer (NSCLC), the overall prognosis of NSCLC remains poor [3] . Immunotherapy is reported to be a relatively effective strategy for NSCLC treatment. However, clinical treatment of NSCLC using immunotherapy is still limited [4, 5] and the underlying mechanisms for immunotherapeutic treatment failures remain largely unknown [6] . Recently, programmed death 1/programmed cell death ligand-1 (PD-1/PD-L1) has become a popular target for immunotherapeutic blockade of co-inhibitory immune pathways [7] . PD-L1 is the major ligand of PD-1 and is expressed on a variety of cell types [8] . Importantly, PD-L1 is expressed on many tumors, including breast cancer, gastric cancer, NSCLC, pancreaticcancer, bladder cancer, cervical cancer, renal cell carcinoma,and melanoma. Inhibition of the PD-1/PD-L1 pathway enhances antitumor immunity by preventing tumor cells from escaping host immune responses. There is growing evidence that high expression of PD-L1 in NSCLC induces T cell apoptosis and is therefore implicated in escape from immunosurveillance [9] . A growing number of studies have demonstrated that overexpression of PD-L1 promotes proliferation and accelerated carcinogenesis in pancreatic cancer [10] . However, the role of PD-L1 in the proliferation of NSCLC has not yet been elucidated. miRNAs are small noncoding single-stranded RNA molecules with mature transcripts of 18 to 25 nucleotides long, which are processed from pre-miRNA by the ribonuclease Dicer. miRNAs act as negative regulators of gene expression by binding to the 3′-untranslated region (UTR) of complementary or partially complementary target messenger RNAs (mRNAs), thereby downregulating target mRNAs via degradation or translational inhibition [11] . miRNAs are reported to be involved in both physiological and pathological processes of pantosomatous organs. Multiple miRNAs that may relate to cancer have been discovered, and numerous studies have demonstrated that several miRNAs are up-regulated (miR-21, miR-17, miR-221) or down-regulated (miR-15, miR-34a, miR-140) in lung cancer in particular [12] [13] [14] . Several studies have reported differential expression of miRNAs in the development of NSCLC [13] . Specifically, it has been reported that miR-140 is down-regulated in NSCLC [15] . However, the role of miR-140 in NSCLC has not been fully investigated, and the target proteins of miR-140 deserve further exploration.
Cyclin E is a key molecule that controls the progression of the cell cycle from S phase to G2/M phase [16] . Increased cyclin E expression has been consistently associated with shorter survival among stage I to IIIa NSCLC patients [17] . This suggests that cyclin E expression is correlated with the aggressiveness of NSCLC [18] [19] [20] . Our bioinformatics analysis, which predicted that PD-L1 and miR-140 are each other's targets, led us to hypothesize that PD-L1 is silenced by miR-140. Furthermore, we hypothesized that expression of PD-L1 is positively related to the expression of cyclin E, and therefore that miR-140 plays a role in regulation of the cell cycle in NSCLC.
In the present study, we measured the expression of miR-140, PD-L1, and cyclin E in clinically-obtained NSCLC cells, and used A549 cells and NCI-H1650 cells to investigate the role of the miR-140/PD-L1/cyclinE pathway in cell proliferation. Our study suggests a crucial role for the miR-140/PD-L1/cyclinE pathway in the pathogenesis of NSCLC, which may suggest a novel mechanism for treatment of NSCLC.
Materials and Methods

Clinical experiment
The study was performed following the guidelines set forth in the Declaration of Helsinki. All subjects gave their informed consent, and experiments were approved by the Veterinary Medicine Animal Care and Use Committee of Hunan Cancer Hospital and the affiliated Cancer Hospital of Xiangya School of Medicine. Lung cancer tissue or normal tissue from patients diagnosed with NSCLC was provided by the Laboratory Animal Center, Xiangya School of Medicine, Central South University, China. Before experiments, the tumor tissue and its peripheral normal tissue were frozen in liquid nitrogen.
The tissues were randomly allocated to two groups (n = 8 per group): the control group (tissue without cancer) and the NSCLC group (tissue with cancer). The lung tissue was conserved for evaluation of expression of mRNA and protein. Cell culture NSCLC cell lines A549 and NCI-H1650were purchased from American Type Culture Collection. Cells were cultured with Dulbecco Minimum Essential Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) in a carbon dioxide incubator at 37°C and 5% CO 2 . Cells were subcultured and seeded into 6-or 24-well cell plates for experiments involving transfection. Cells were digested using 0.2% trypsogen prior to mRNA or protein analysis.
RNA extraction and reverse transcription
Total RNA was extracted by using TRIzol reagent (TakaRa, Dalian, China). The concentration and purity of RNA was determined spectrophotometrically. Two hundred ng of RNA from each sample was used for the reverse transcription reaction, which was conducted according to the instructions of a transcription kit (DRR037A; TaKaRa, Dalian, China).
Bio-informatics analysis
We focused on the gene PD-L1, which is up-regulated, and the RNA miR-140, which is down-regulated, in NCSLC tissue. The target gene of miR-140 and the target miRNA of PD-L1 were predicted using the online systems TargetScan and miBase.
Real-time PCR
Real-time PCR was used to quantitatively analyze the levels of PD-L1 mRNA, cyclin E mRNA, and miR-140 in lung tissue or A549 and NCI-H1650cells using SYBR Premix Ex Taq (TaKaRa Dalian, China) with the ABI 7300 real-time PCR system. The real-time PCR primers for the genes PD-L1, cyclin E, and β-actin are displayed in Table 1 . Primers for miR-140 were purchased from RuiBo. Data analysis was performed using the comparative Ct method on ABI software. The result was adjusted by the ratio of PD-L1 or cyclin E to β-actin, or by the ratio of miR-140 to U6.
Western blotting
The total protein in each sample was extracted using a protein lysate supplemented with 1% phenylmethylsulfonyl fluoride (PMSF), which protects proteins from degradation by endogenous protease. Centrifuging at 12000 r/min produced a supernatant which was used for either denaturation or measuring protein concentration. 40 μg protein was used for Western blot analysis by following these steps: Samples were separated on an SDS-PAGE (10%) gel, then transferred to a polyvinylidene fluoride membrane. The membranes were incubated with rabbit anti-PD-L1 and anti-cyclin E, followed by horseradish peroxidaseconjugated secondary antibodies. To ensure equal loading, blots were also incubated with mouse anti-β-actin antibodies (Millipore, Billerica, MA, USA). Band signal strength was determined using enhanced chemiluminescence (ECL kit, Amersham Biosciences, Piscataway, NJ, USA) through the Molecular Imager ChemiDoc XRS System (Bio-Rad, Philadelphia, USA).The densitometric analysis was conducted with Image J 1.43 software (National Institutes of Health).
Plasmid transfection
We constructed two plasmids: wild type(PD-L1-WT) and mutated(PD-L1-MU), each with a luciferase reporter gene. The wild type plasmid contained the seed sequence "UGUGGUA", while the mutated plasmid contained the sequence "UGUAGUA". The two plasmids were amplified in DH5ɑ competent cells and then transfected into A549 and NCI-H1650cellson a 24-well plate at a concentration of 50ng per well. Meanwhile, A549 cells were co-transfected with miR-140 mimics or inhibitors as described below. Finally, cells were collected for analysis of relative luciferase activity.
Transfection with miR-140 mimics
Experiments involving transfection of miR-140 mimics were conducted according to the instructions Table 1 . The primer sequences were as follows:
Primer sequenze
Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry of the manufacturer. Before transfection, a mix including miR-140 mimics and transfection agent lip2000 were prepared. Then, the mix was added into 6-or 24-well plates of A549 orNCI-H1650cell cultures to make a final concentration of 80 nM. Transfection proceeded for 6 h, after which the cells were collected for mRNA or protein analysis.
Transfection with PD-L1 siRNA PD-L1 siRNA transfection experiments were conducted according to the instructions of a commercial kit. Before transfection, a mix including PD-L1 siRNA and transfection agent EntransterTM-R4000 was prepared. Then, the mix was added into 6-or 24-well plates of A549 orNCI-H1650 cell cultures to make a final concentration of 2 pmol/L. Transfection proceeded for 48h, after which the cells were collected for mRNA or protein analysis.
MTT staining
The MTT assay was used according to the manufacturer's instructions to evaluate the proliferation of those A549 cells which were treated with miR-140 mimics. Living cells can reduce exogenous MTT to formazan, which creates a purple sediment in dimethyl sulfoxide (DMSO). The optical density of this sediment, which is proportional to the number of proliferating cells, was measured at 490nm using a spectrophotometer.
Cell cycle measurement
Propidium iodide (PI) staining was used for cell cycle analysis according to the instructions of a commercial kit. A cell suspension was prepared in phosphate buffered saline (PBS), centrifuged at 1500 rpm, fixed with 70% alcohol at -20°C overnight, centrifuged again, and washed in PBS. PI solution was added to make a final concentration of 50μg/ml, after which the cells were held in the dark for 30 min. We measured distribution of cell phases using flowcytometry, and analyzed the data with Flowjo software.
Statistical analysis
All assays were repeated independently at least three times. All data were expressed as mean±SEM and were analyzed with SPSS 18.0 statistical software.Differences in measured values among the multiple groups were analyzed using analysis of variance with Bonferroni's multiple comparison correction. The Chi-square test was used to compare the frequency distributions between groups. Pearson correlation coefficients were used for correlation analysis. Differences were considered significant at p< 0.05.
Results
miR-140 expression is decreased in NSCLC
To begin investigating the role of miR-140 in tumor tissue, we measured the levels of expression of miR-140 in clinically-obtained samples of NSCLC. As shown in Fig. 1A , expression of miR-140, measured with realtime PCR, was significantly decreased in tumor tissues compared with the controls. This suggests that lower miR-140 levels are associated with NSCLC. We examined the relationship between expression of miR-140 and tumor size, and found that expression of miR-140 was negatively correlated with tumor diameter (Fig. 1B) . These data suggest that miR-140 plays an important role in NSCLC.
Gene expression of PD-L1 and cyclin E are altered in NSCLC
Bioinformatic analysis using TargetScan and miBase revealed that PD-L1 is a poten- Fig. 2A) .
To investigate the role of PD-L1 and elucidate the relationship between PD-L1 and miR-140 in NSCLC, the levels of expression of PD-L1 and miR-140 were measured using western blot and RT-PCR in clinically-obtained NSCLC cells. As shown in Fig. 2 , NSCLC was associated with significantly higher expression of PD-L1 compared to control cells. Consistently, analysis revealed an inverse correlation between expression of miR-140 and PD-L1 (Fig. 2D) . It has been reported that many other genes are altered in NSCLC, including those affecting the cell cycle such as cyclin E. To further investigate the role of cyclin E in NSCLC, we measured the expression of cyclin E in clinically-obtained NSCLC cells. As shown in Fig. 2E and 2F, the expression of cyclin E is significantly upregulated in NSCLC cells compared to controls.
Since cell proliferation and apoptosis are two key aspects of tumor progression, we hypothesized that both play a pivotal role in NSCLC. We compared the expression of PD-L1, a gene controlling apoptosis, and the expression of cyclin E, a gene controlling proliferation, and found that they were positively correlated (Fig. 2G) . These results indicate that PD-L1 and cyclin E are key players in NSCLC.
miR-140 directly regulates PD-L1 expression
To confirm the above hypothesis, we co-transfected cells with plasmids containing miR-140 mimics and plasmids containing either wild-type (WT) or mutated (MU) PD-L1/ luciferase reporter genes. As shown in Fig. 3A , the expression of miR-140 was significantly up-regulated in A549 and NCI-H1650 cells after transfection with miR-140 mimics. This suggests that we successfully transfected functional miR-140 mimics into both cell lines. We found that over-expression of miR-140 significantly suppressed PD-L1 expression (both mRNA and protein) (Fig. 3B, C) . These results suggest that miR-140 is involved in the regulation of PD-L1 expression. Finally, miR-140 mimics significantly decreased the relative luciferase activity in the PD-L1-WT group, but not in the PD-L1-MU group. In addition, miR-140 inhibitors partly reversed the relative decrease in luciferase activity which had been caused by the miR-140 mimics (Fig. 3D) . These results indicate that miR-140 suppresses PD-L1 by directly targeting its 3' UTR.
Overexpression of miR-140 or inhibition of PD-L1 decreases cyclin E expression
Previous studies have found that miR-140 levels are negatively correlated with PD-L1 expression, while PD-L1 expression is positively correlated with cyclin E expression [21, 22] . We therefore hypothesized a relationship between miR-140, PD-L1, and cyclin E. To investigate their roles in expression of cyclin E, the expression of miR-140 and PD-L1were miR-140 mimics (50μM); +control siRNA: negative control siRNA; +PD-L1siRNA: siRNA specific against PD-L1; All values are expressed as means ±SEM. vs control, * p＜0.05.
Fig. 4
Cell Fig. 4 , miR-140 mimics significantly inhibited expression of cyclin E (Fig. 4A, B) . PD-L1-specific siR-NA was used to investigate the effect of PD-L1 on cyclin E. siRNA specific to PD-L1 significantly decreased the expression of both PD-L1 (Fig. 4C, D) and cyclin E (Fig.  4E, F) . These results suggest that PD-L1 and miR-140 are involved in the regulation of cyclin E. significantly decreased the optical density at days 4 and 5 in bothA549 and NCI-H1650 cells (Fig.  5A) . These results indicate that miR-140 plays an important role in cellular proliferation in NSCLC. To further investigate the effect of miR-140 on the cell cycle, we used PI staining with analysis of the distributions of cell phases. As shown in Fig. 5B and 5C, increased miR-140 contributed to S phase stagnation, without progression to G2/M phase of A549 and NCI-H1650 cells. These results suggest that miR-140 can regulate the cell cycle by inhibiting cellular proliferation. 
Discussion
In this study, we investigated the roles and mechanisms of miR-140, PD-L1, and cyclin E in NSCLC. We found that NSCLC is associated with low expression of miR-140. Bioinformatics analysis predicted a relationship between miR-140 and PD-L1, we found that miR-140 directly suppresses PD-L1 by interacting with its 3'UTR. Overexpression of miR-140 significantly inhibits the proliferation of A549 and NCI-1650 cells. This may be in part due to its effect on cyclin E expression. These results suggest that the miR-140/PD-L1/cyclinE pathway might be a potential therapeutic target for inhibition of cell proliferation in NSCLC.
Several lines of study have reported that some important, functional miRNAs can be detected in the systemic circulation of patients with NSCLC, these may be very valuable in the diagnosis and prognosis of this disease [23, 24] . Accumulating evidence has shown that miRNAs, including miRNA-377, miR-152, miRNA-126 and miRNA-133b, are involved in the progression and metastasis of NSCLC through various targeted genes includingAEG-1 [25] andneuropilin-1 [26] . These findings suggest that miRNAs might act as novel predictor biomarkers of the progression and metastasis of NSCLC [27] .
miR-140 has been intensively used in cancer research, but its role in NSCLC had been poorly understood. In the present study, we found that miR-140 is significantly downregulated in NSCLC, that miR-140 overexpression inhibits NSCLC cell proliferation, and that one target of miR-140 is PD-L1. To corroborate the findings of whether miR-140 expression is involved in tumor growth, migration, and metastasis, we performed the transwell experiment and scratching test. In vitro and in vivo studies have confirmed the antitumor efficacy of PD-1 and PD-L1, which have emerged as important targets for immunotherapy. PD-1 is a type 1 transmembrane protein of the Ig superfamily [4, 7, 8] , consisting of an extracellular N-terminal IgV-like domain, a transmembrane domain, and a cytoplasmic tail [4] . It engages in inhibitory signal transmission and is expressed on activated immune cell types. PD-1 has two ligands, PD-L1 and PD-L2 , which belong to the B7 family. PD-L1 is the major ligand and is expressed on a variety of cell types, importantly including many tumors such as lung cancer. Previous studies have reported that the PD-1/PD-L1 system is involved in tumor immunity and is closely associated with tumorigenesis and invasiveness [28] [29] [30] [31] . Increased expression of PD-L1 is significantly associated with poor prognosis in many cancers. Specifically in human NSCLC, it has been associated with tumor aggressiveness and postoperative recurrence [32] . One study demonstrated that increased expression of PD-L1 in lung cancer may contribute to escape of tumor cells from the immune response by suppressing maturation of tumor-infiltrating dendritic cells [33] . These interactions may also play a pivotal role in the reduction of specific immune cell apoptosis. Taken together, these data suggest that PD-L1 is involved in tumor infiltration and cell proliferation in NSCLC. Thus, it is reasonable to consider that the blockade of the PD-L1/PD-1 interaction might be a promising anticancer immunotherapy, but controversy still exists regarding the clinical prognostic significance of PD-L1 expression on tumors.
Many studies have indicated consensus agreement that therapeutic blockade of PD-L1 might break multiple layers of immune inhibition, allowing an effective anti-tumor response. Recent studies have demonstrated that PD-L1 is a direct target of HIF1ɑ [34] , which suggests that PD-L1 is involved in regulation of cellular proliferation. Indeed, over-expression of PD-L1 has been correlated with malignant cell proliferation in pancreatic cancer [35] . These results support the link between PD-L1 and proliferation of cancer cells; in this study, we found that expression of PD-L1 is up-regulated in NSCLC.
Cyclin E is a nuclear protein that is essential for cell cycle progression, DNA replication, and centrosome duplication. Numerous types of cancers are highly associated with dysregulation of cyclin E. Dysregulation of cyclin E occurs in more than 90 % of lung, liver, and gastrointestinal cancers, in addition to bone and breast cancers. Constitutive overexpression of cyclin E induces chromosome instability, impairs normal cell cycle progression, and triggers tumor development in transgenic animal models [16] . Earlier studies have demonstrated that cyclin E is involved in tumor growth in various cell types, while more Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry
